Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VSC011
MIFTS: 66

Vasculitis

Categories: Blood diseases, Cardiovascular diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vasculitis

About this section

MalaCards integrated aliases for Vasculitis:

Name: Vasculitis 12 77 54 30 56 6 44 45 15 64 17 74
Autoimmune Vasculitis 54 74
Angiitis 12 54
Vasculitis, Autoimmune 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:865
MeSH 45 D014657
NCIt 51 C26912
SNOMED-CT 69 31996006
Sources

Summaries for Vasculitis

About this section
NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 52759Disease definitionVasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis; see these terms), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease; see these terms), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis; see these terms). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behçet disease, see this term) to relatively minor skin disease.Visit the Orphanet disease page for more resources.

MalaCards based summary : Vasculitis, also known as autoimmune vasculitis, is related to anca-associated vasculitis and lymphocytic vasculitis, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs alemtuzumab and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and t cells, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A vascular disease that is characterized by inflammation of the blood vessels.

MedlinePlus : 44 Vasculitis is an inflammation of the blood vessels. It happens when the body's immune system attacks the blood vessel by mistake. It can happen because of an infection, a medicine, or another disease. The cause is often unknown. Vasculitis can affect arteries, veins and capillaries. Arteries are vessels that carry blood from the heart to the body's organs. Veins are the vessels that carry blood back to the heart. Capillaries are tiny blood vessels that connect the small arteries and veins. When a blood vessel becomes inflamed, it can Narrow, making it more difficult for blood to get through Close off completely so that blood can't get through Stretch and weaken so much that it bulges. The bulge is called an aneurysm. If it bursts, it can cause dangerous bleeding inside the body. Symptoms of vasculitis can vary, but usually include fever, swelling and a general sense of feeling ill. The main goal of treatment is to stop the inflammation. Steroids and other medicines to stop inflammation are often helpful. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 64 About vasculitis: Vasculitis (vas-kyu-LI-tis) is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition.“Inflammation” refers to the body’s response to injury, including injury to the blood vessels. Inflammation may involve pain, redness, warmth, swelling, and loss of function in the affected tissues.In vasculitis, inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected.

Wikipedia : 77 Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins... more...

Sources

Related Diseases for Vasculitis

About this section

Diseases in the Vasculitis family:

Autoimmune Vasculitis

Diseases related to Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1006)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 34.4 MPO PRTN3 SERPINA1
2 lymphocytic vasculitis 34.3 ICAM1 SELE VCAM1
3 hypersensitivity vasculitis 34.3 CRP MEFV MPO PRTN3
4 rheumatoid vasculitis 34.1 CX3CL1 ICAM1 SELE TNF VCAM1
5 autoimmune vasculitis 33.8 CTSG ELANE
6 henoch-schoenlein purpura 33.3 CRP ICAM1 MEFV MPO VCAM1
7 churg-strauss syndrome 33.2 MPO PRTN3 THBD TNF
8 temporal arteritis 33.0 APOH CRP TNF
9 microscopic polyangiitis 32.9 CX3CL1 MPO TNF
10 kawasaki disease 32.8 CRP ELANE SELE TNF
11 arthus reaction 32.6 ELANE ICAM1 TNF
12 granulomatous angiitis 32.5 CRP PRTN3 THBD
13 alpha-1-antitrypsin deficiency 32.5 BPI ELANE SERPINA1
14 polyarteritis nodosa 32.4 APOH CRP MEFV MPO PRTN3 SELE
15 granulomatosis with polyangiitis 32.3 BPI CTSG ELANE MPO PRTN3 SERPINA1
16 behcet syndrome 32.0 APOH CRP MEFV SELE THBD TNF
17 vascular disease 31.4 APOH CRP ELANE MPO SELE THBD
18 purpura 30.8 APOH CRP THBD TNF VWF
19 crescentic glomerulonephritis 30.6 BPI CTSG ICAM1 MPO VCAM1
20 glomerulonephritis 30.6 CD40LG ICAM1 MPO PRTN3 VCAM1
21 rapidly progressive glomerulonephritis 30.5 CRP ELANE ICAM1 MPO PRTN3
22 mononeuritis multiplex 30.5 CRP MPO
23 endocarditis 30.5 APOH CRP TNF VCAM1
24 ulcerative colitis 30.5 BPI CRP MPO PRTN3 TNF
25 familial mediterranean fever 30.5 CRP MEFV TNF
26 aortitis 30.4 CRP MPO
27 infective endocarditis 30.4 APOH CRP TNF
28 immune-complex glomerulonephritis 30.4 ICAM1 MPO VCAM1
29 cutaneous lupus erythematosus 30.3 ICAM1 SELE TNF
30 multiple sclerosis 30.3 ICAM1 TNF TNFSF13B VCAM1
31 respiratory failure 30.3 CRP ELANE SERPINA1 TNF
32 pericarditis 30.3 CRP MEFV TNF
33 cholangitis 30.2 CRP PRTN3 TNF
34 chorioamnionitis 30.2 CRP ELANE TNF
35 cerebral aneurysms 30.2 ELANE MPO
36 erysipelas 30.2 ELANE MEFV TNF
37 spotted fever 30.2 THBD TNF VWF
38 localized scleroderma 30.2 SELE TNF VCAM1
39 inflammatory bowel disease 30.1 CRP MPO S100A9 TNF
40 connective tissue disease 30.1 APOH CD40LG TNF TNFSF13B
41 stroke, ischemic 30.1 APOH CRP THBD VWF
42 reactive arthritis 30.1 BPI CRP TNF
43 juvenile rheumatoid arthritis 30.1 CRP S100A9 TNF
44 takayasu arteritis 30.1 CRP SELE THBD TNF VCAM1 VWF
45 thrombophilia due to thrombin defect 30.1 APOH THBD VWF
46 shwartzman phenomenon 30.1 ICAM1 TNF VCAM1
47 intermittent claudication 30.1 APOH CRP VWF
48 appendicitis 30.0 CRP MPO TNF
49 autoimmune disease 30.0 APOH CD40LG TNF TNFSF13B
50 critical limb ischemia 30.0 SELE TNF

Graphical network of the top 20 diseases related to Vasculitis:



Diseases related to Vasculitis
Sources

Symptoms & Phenotypes for Vasculitis

About this section

UMLS symptoms related to Vasculitis:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Vasculitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 CD40LG CTSG CX3CL1 ELANE ICAM1 MEFV
2 cellular MP:0005384 10.1 CD40LG CX3CL1 ICAM1 MEFV PRTN3 S100A9
3 cardiovascular system MP:0005385 10.07 CD40LG CRP CX3CL1 ICAM1 MPO SELE
4 homeostasis/metabolism MP:0005376 10.03 APOH CD40LG CRP CX3CL1 ELANE ICAM1
5 immune system MP:0005387 9.89 CD40LG CRP CTSG CX3CL1 ELANE ICAM1
6 mortality/aging MP:0010768 9.47 APOH CD40LG CTSG ELANE ICAM1 MEFV
Sources

Drugs & Therapeutics for Vasculitis

About this section

PubMedHealth treatment related to Vasculitis: 64

Treatment for vasculitis will depend on the type of vasculitis you have, which organs are affected, and the severity of the condition.People who have severe vasculitis are treated with prescription medicines. Rarely, surgery may be done. People who have mild vasculitis may find relief with over-the-counter pain medicines, such as acetaminophen, aspirin, ibuprofen, or naproxen.The main goal of treating vasculitis is to reduce inflammation in the affected blood vessels. This usually is done by reducing or stopping the immune response that caused the inflammation.

Drugs for Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 1 216503-57-0
2
Dapsone Approved, Investigational Phase 4,Phase 2 80-08-0 2955
3
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
8
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 446-86-6 2265
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
11
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
12
Methotrexate Approved Phase 4,Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 22916-47-8 4189
15
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
16
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
17
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 6473866 445643 439492
18
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
19
Anthralin Approved Phase 4 1143-38-0
20
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
21
Colchicine Approved Phase 4,Phase 2 64-86-8 2833 6167
22
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
23
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
24
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 46507594 772
26
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
27
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
28
Adenosine Approved, Investigational Phase 4,Not Applicable 58-61-7 60961
29
Pentoxifylline Approved, Investigational Phase 4,Phase 2 6493-05-6 4740
30
Pravastatin Approved Phase 4,Phase 2 81093-37-0 54687
31
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
32
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
34
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
35
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
36
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2920-86-7
37 Tocotrienol Investigational Phase 4 6829-55-6
38 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 522)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
4 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
5 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
6 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
7 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
8 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
9 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
10 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
11 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
12 Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
13 Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis Completed NCT00940862 Phase 4
14 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
15 Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Completed NCT00369382 Phase 4 cyclosporine or tacrolimus;sirolimus
16 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
17 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation Completed NCT00048165 Phase 4 Daclizumab;Methylprednisolone;Mycophenolate mofetil;Placebo;cyclosporine
18 Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease Completed NCT01524939 Phase 4 immunoglobulin G
19 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
20 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
21 Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins Completed NCT02346058 Phase 4 Esarin Gel
22 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
23 Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins Completed NCT00377806 Phase 4 Diclofenac gel
24 Management of Superficial Thrombophlebitis Completed NCT00264381 Phase 4 Dalteparin sodium injection
25 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Recruiting NCT02749292 Phase 4 Rituximab
26 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
27 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
28 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
29 Tocilizumab Plus a Short Prednisone Taper for GCA Recruiting NCT03726749 Phase 4 Tocilizumab;Prednisone
30 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
31 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Active, not recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
32 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
33 The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis Enrolling by invitation NCT02082717 Phase 4 potassium chloride replacement;Experimental - 4% Sodium Bicarbonate
34 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
35 Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children Suspended NCT01794767 Phase 4 0,9% NaCl flush;Heparin 50U/ml
36 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Terminated NCT00128895 Phase 4 azathioprine
37 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
38 Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study Terminated NCT00384618 Phase 4 pravastatin;vitamin E
39 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
40 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
41 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
42 Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People Terminated NCT00418470 Phase 4
43 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
44 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
45 Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis Unknown status NCT03096275 Phase 3 MMF;CYC;Glucocorticoids;MTX;AZA
46 Pain and Music Therapy in Patients Suffering Arteritis Unknown status NCT01323504 Phase 3
47 Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Unknown status NCT01297959 Phase 3 E-101 Solution 300 GU/ml;Saline solution
48 Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change Unknown status NCT00103636 Phase 2, Phase 3
49 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
50 Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide

Search NIH Clinical Center for Vasculitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: vasculitis

Sources

Genetic Tests for Vasculitis

About this section

Genetic tests related to Vasculitis:

# Genetic test Affiliating Genes
1 Vasculitis 30
Sources

Anatomical Context for Vasculitis

About this section

MalaCards organs/tissues related to Vasculitis:

42
Neutrophil, Skin, T Cells, B Cells, Kidney, Endothelial, Thyroid
Sources

Publications for Vasculitis

About this section

Articles related to Vasculitis:

(show top 50) (show all 5690)
# Title Authors Year
1
Rare presentation of immunoglobulin A vasculitis as acute pancreatitis in a 10-year-old girl. ( 30484921 )
2019
2
Acute Posterior Multifocal Placoid Pigment Epitheliopathy Complicated by Fatal Cerebral Vasculitis. ( 30676416 )
2019
3
Extensive purpuric lesions due to vitamin C deficiency and leucocytoclastic vasculitis as the initial sign of lung adenocarcinoma. ( 30687951 )
2019
4
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management. ( 30484240 )
2019
5
Clinical impact of alpha-1-antitrypsin deficiency in ANCA-associated vasculitis: results from a French retrospective monocentric cohort of 142 consecutive patients. ( 30824651 )
2019
6
Incidentally Diagnosed Alport Syndrome in a Patient with Drug-Induced Vasculitis. ( 31093390 )
2019
7
MYCYC: unravelling the long road ahead in ANCA-associated vasculitis. ( 30894345 )
2019
8
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. ( 30896460 )
2019
9
Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Causes Aortic Valve Degeneration and Severe Aortic Regurgitation. ( 30930460 )
2019
10
Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis. ( 30932727 )
2019
11
PR3-ANCA-associated vasculitis is associated with a specific motif in the peptide-binding cleft of HLA-DP molecules. ( 30938436 )
2019
12
A Case of ANCA-Associated Vasculitis. ( 30952628 )
2019
13
Rapid progression to end-stage renal disease in a young female with mixed immunopathological features of lupus and ANCA-associated vasculitis. ( 30968562 )
2019
14
Occurrence of cerebral small vessel disease at diagnosis of MPO-ANCA-associated vasculitis. ( 30982149 )
2019
15
Estimating the Change in Renal Function During the First Year of Therapy in ANCA-Associated Vasculitis. ( 30993234 )
2019
16
No Difference in Cognitive Dysfunction Among Patients with ANCA-Associated Vasculitis, Rheumatoid Arthritis or Chronic Kidney Disease. ( 31030697 )
2019
17
Plasma exchange is highly effective for ANCA-associated vasculitis patients with rapidly progressive glomerulonephritis who have advanced to dialysis dependence: A single-center case series. ( 31033151 )
2019
18
Comparison of the birmingham vasculitis activity score and the five factors score to assess survival in anca-associated vasculitis. ( 31033198 )
2019
19
Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. ( 31049594 )
2019
20
Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series. ( 31088509 )
2019
21
ANCA-Associated Vasculitis in Inflammatory Bowel Disease. ( 31093814 )
2019
22
Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. ( 31102526 )
2019
23
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2019
24
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. ( 29887327 )
2019
25
Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. ( 29996690 )
2019
26
2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. ( 30001655 )
2019
27
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. ( 30074077 )
2019
28
ANCA associated vasculitis: experience of a tertiary care referral center. ( 30095143 )
2019
29
Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. ( 30168048 )
2019
30
Targeted immunotherapy strategies in ANCA-associated vasculitis. ( 30201478 )
2019
31
Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis. ( 30446886 )
2019
32
Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis. ( 30607566 )
2019
33
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. ( 30612116 )
2019
34
Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis. ( 30635307 )
2019
35
Author Correction: Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. ( 30655606 )
2019
36
Low-dose rituximab as induction therapy for ANCA-associated vasculitis. ( 30680533 )
2019
37
Updating OMERACT Core Set of Domains for ANCA-Associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability and Health. ( 30709951 )
2019
38
Prognostic nutritional index is associated with disease severity and relapse in ANCA-associated vasculitis. ( 30729693 )
2019
39
Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: case series and review of literature. ( 30734199 )
2019
40
Changing landscape of immunosuppression in ANCA-associated vasculitis. ( 30755415 )
2019
41
Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort. ( 30767717 )
2019
42
Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. ( 30777023 )
2019
43
Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective monocentric study. ( 30798998 )
2019
44
Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. ( 30805643 )
2019
45
Diffuse alveolar hemorrhage in a patient with ANCA-associated vasculitis after thyroidectomy: A case report. ( 30813199 )
2019
46
Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. ( 30818380 )
2019
47
Aortitis and pachymeningitis: an unusual combination in granulomatosis with polyangiitis (myeloperoxidase-associated vasculitis). ( 30696638 )
2019
48
Connecting the dots: a story of unknown fever, acute coronary syndrome and pan-aortitis-an occult relapse of a large vessel vasculitis. ( 31061187 )
2019
49
Small vessel multi-organ vasculitis and marantic endocarditis complicating rheumatoid arthritis. ( 31070579 )
2019
50
Extracellular vesicles in autoimmune vasculitis - Little dirts light the fire in blood vessels. ( 30959208 )
2019
Sources

Variations for Vasculitis

About this section

ClinVar genetic disease variations for Vasculitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CCM2 NM_031443.3(CCM2): c.1234C> T (p.Arg412Trp) single nucleotide variant Uncertain significance rs544276945 GRCh37 Chromosome 7, 45115555: 45115555
2 CCM2 NM_031443.3(CCM2): c.1234C> T (p.Arg412Trp) single nucleotide variant Uncertain significance rs544276945 GRCh38 Chromosome 7, 45075956: 45075956
3 COL4A2 NM_001846.3(COL4A2): c.1776+13A> G single nucleotide variant Uncertain significance rs1555330577 GRCh37 Chromosome 13, 111114744: 111114744
4 COL4A2 NM_001846.3(COL4A2): c.1776+13A> G single nucleotide variant Uncertain significance rs1555330577 GRCh38 Chromosome 13, 110462397: 110462397
Sources

Expression for Vasculitis

About this section
Search GEO for disease gene expression data for Vasculitis.
Sources

Pathways for Vasculitis

About this section

Pathways related to Vasculitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 67
Show member pathways
 13.24 CD40LG ICAM1 PRTN3 TNF TNFSF13B VCAM1
2
Innate Immune System 67
Show member pathways
 13.12 BPI CD40LG CRP CTSG ELANE ICAM1
3
NF-kappaB Signaling 4
12.42 CD40LG MPO TNF TNFSF13B VCAM1
4
Defensins 67
Show member pathways
 12.24 BPI CTSG ELANE PRTN3 S100A9
5
Selenium Micronutrient Network 1
Show member pathways
 12.19 CRP ICAM1 MPO TNF
6
Fluid shear stress and atherosclerosis 38
12.02 ICAM1 SELE THBD TNF VCAM1
7
Cell adhesion molecules (CAMs) 38
11.99 CD40LG ICAM1 SELE VCAM1
8
TNF signaling pathway 38
11.87 CX3CL1 ICAM1 SELE TNF VCAM1
9
Matrix Metalloproteinases 1
Show member pathways
 11.78 CTSG ELANE TNF
10
AGE-RAGE signaling pathway in diabetic complications 38
11.77 ICAM1 SELE THBD TNF VCAM1
11
Amoebiasis 38
11.76 CTSG SERPINB1 TNF
12
Rheumatoid arthritis 38
11.73 ICAM1 TNF TNFSF13B
13
NF-kappa B signaling pathway 38
11.72 CD40LG ICAM1 TNF TNFSF13B VCAM1
14
C-MYB transcription factor network 1
11.64 ELANE MPO PRTN3
15
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.61 CD40LG TNF TNFSF13B
16
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 CD40LG ICAM1 SELE TNF VCAM1
17
amb2 Integrin signaling 1
11.44 ELANE ICAM1 MPO TNF
18
Thromboxane A2 receptor signaling 1
11.37 ICAM1 SELE VCAM1
19
African trypanosomiasis 38
11.27 ICAM1 SELE TNF VCAM1
20
G-protein signaling_RhoB regulation pathway 23
11.08 CD40LG CX3CL1 TNF TNFSF13B
21
Malaria 38
11.04 CD40LG ICAM1 SELE TNF VCAM1
22
LDL Oxidation in Atherogenesis 65
10.66 ICAM1 MPO TNF VCAM1
Sources

GO Terms for Vasculitis

About this section

Cellular components related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.91 APOH CD40LG CTSG CX3CL1 ELANE ICAM1
2 azurophil granule lumen GO:0035578 9.77 BPI CTSG ELANE MPO PRTN3
3 membrane raft GO:0045121 9.71 ICAM1 PRTN3 SELE TNF
4 secretory granule GO:0030141 9.61 CTSG ELANE MPO
5 collagen-containing extracellular matrix GO:0062023 9.61 APOH CTSG ELANE ICAM1 PRTN3 S100A9
6 extracellular space GO:0005615 9.58 APOH BPI CD40LG CRP CTSG CX3CL1
7 extracellular exosome GO:0070062 10.1 APOH BPI CTSG ELANE ICAM1 MPO
8 extracellular region GO:0005576 10.03 APOH BPI CD40LG CRP CTSG CX3CL1

Biological processes related to Vasculitis according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CD40LG CRP CX3CL1 MEFV S100A9 SELE
2 regulation of immune response GO:0050776 9.95 CD40LG ICAM1 TNFSF13B VCAM1
3 extracellular matrix organization GO:0030198 9.93 ICAM1 TNF VCAM1 VWF
4 cytokine-mediated signaling pathway GO:0019221 9.93 CX3CL1 ICAM1 PRTN3 TNF VCAM1
5 defense response to bacterium GO:0042742 9.93 BPI CTSG ELANE MPO S100A9 TNF
6 leukocyte migration GO:0050900 9.92 ELANE ICAM1 SELE TNF
7 neutrophil degranulation GO:0043312 9.92 BPI CTSG ELANE MPO PRTN3 S100A9
8 blood coagulation GO:0007596 9.91 PRTN3 SERPINA1 THBD VWF
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 CD40LG CX3CL1 ICAM1 S100A9 TNF
10 defense response to Gram-positive bacterium GO:0050830 9.85 CRP CTSG TNF
11 positive regulation of inflammatory response GO:0050729 9.85 CX3CL1 S100A9 TNF
12 regulation of inflammatory response GO:0050727 9.82 S100A9 SELE TNF
13 tumor necrosis factor-mediated signaling pathway GO:0033209 9.81 CD40LG TNF TNFSF13B
14 positive regulation of T cell proliferation GO:0042102 9.8 CD40LG TNFSF13B VCAM1
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 CX3CL1 ELANE TNF
16 hemostasis GO:0007599 9.77 SERPINA1 THBD VWF
17 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.74 ICAM1 SELE VCAM1
18 defense response to fungus GO:0050832 9.71 CTSG ELANE MPO S100A9
19 negative regulation of interleukin-6 production GO:0032715 9.69 BPI CX3CL1 TNF
20 negative regulation of blood coagulation GO:0030195 9.68 APOH THBD
21 negative regulation of fibrinolysis GO:0051918 9.67 APOH THBD
22 leukocyte tethering or rolling GO:0050901 9.67 SELE TNF VCAM1
23 leukocyte cell-cell adhesion GO:0007159 9.67 CD40LG ICAM1 SELE VCAM1
24 negative regulation of interleukin-1 beta production GO:0032691 9.66 CX3CL1 MEFV
25 positive regulation of immune response GO:0050778 9.66 CTSG ELANE
26 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.65 ELANE TNF
27 negative regulation of lipid storage GO:0010888 9.65 CRP TNF
28 antimicrobial humoral response GO:0019730 9.65 BPI CTSG ELANE PRTN3 S100A9
29 acute inflammatory response to antigenic stimulus GO:0002438 9.63 ELANE ICAM1
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.59 ICAM1 TNF
31 membrane to membrane docking GO:0022614 9.58 ICAM1 VCAM1
32 regulation of immunoglobulin secretion GO:0051023 9.58 CD40LG TNF
33 immunoglobulin secretion GO:0048305 9.56 CD40LG TNFSF13B
34 response to yeast GO:0001878 9.55 ELANE MPO
35 negative regulation of growth of symbiont in host GO:0044130 9.46 CTSG ELANE MPO TNF
36 leukocyte migration involved in inflammatory response GO:0002523 9.26 CX3CL1 ELANE S100A9 SELE
37 response to lipopolysaccharide GO:0032496 9.17 CTSG ELANE ICAM1 MPO SELE THBD
38 immune response GO:0006955 10 BPI CD40LG CTSG CX3CL1 TNF TNFSF13B

Molecular functions related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 CD40LG CX3CL1 TNF TNFSF13B
2 heparin binding GO:0008201 9.56 APOH CTSG ELANE MPO
3 integrin binding GO:0005178 9.46 CX3CL1 ICAM1 VCAM1 VWF
4 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG TNF TNFSF13B
5 protease binding GO:0002020 8.92 ELANE SERPINA1 TNF VWF
Sources

Sources for Vasculitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....